0000000000123260

AUTHOR

Rodrigo Alonso

showing 12 related works from this author

Summary Report of MINSIS Workshop in Madrid

2010

Recent developments on tau detection technologies and the construction of high intensity neutrino beams open the possibility of a high precision search for non-standard {\mu} - {\tau} flavour transition with neutrinos at short distances. The MINSIS - Main Injector Non-Standard Interaction Search- is a proposal under discussion to realize such precision measurement. This document contains the proceedings of the workshop which took place on 10-11 December 2009 in Madrid to discuss both the physics reach as well as the experimental requirements for this proposal.

High Energy Physics - Experiment (hep-ex)High Energy Physics - PhenomenologyHigh Energy Physics - Phenomenology (hep-ph)FOS: Physical sciencesHigh Energy Physics - ExperimentParticle Physics - Phenomenology
researchProduct

$SU(2)\times U(1)$ gauge invariance and the shape of new physics in rare $B$ decays

2014

New physics effects in $B$ decays are routinely modeled through operators invariant under the strong and electromagnetic gauge symmetries. Assuming the scale for new physics is well above the electro-weak scale, we further require invariance under the full Standard-Model gauge symmetry group. Retaining up to dimension-6 operators, we unveil new constraints between different new-physics operators that are assumed to be independent in the standard phenomenological analyses. We illustrate this approach by analyzing the constraints on new physics from rare $B_{q}$ (semi-)leptonic decays.

High Energy Physics - PhenomenologyHigh Energy Physics - Phenomenology (hep-ph)FOS: Physical sciences
researchProduct

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collabora…

2018

PubMed: 30270054

International CooperationMÉTODOS EPIDEMIOLÓGICOS030204 cardiovascular system & hematologyNationwide surveyGlobal HealthHealth Services AccessibilityDoenças Cardio e Cérebro-vascularesMOLECULAR-GENETICS0302 clinical medicineRisk FactorsPrevalenceCARDIOVASCULAR RISK-FACTORS030212 general & internal medicineCooperative BehaviorDEFECTIVE APOLIPOPROTEIN B-100GENERAL-POPULATIONeducation.field_of_studymedicine.diagnostic_testAnticholesteremic AgentsFamilial hypercholesterolaemia; FHSC; Primary dyslipidaemia; Anticholesteremic Agents; Biomarkers; Cholesterol LDL; Cooperative Behavior; Genetic Predisposition to Disease; Health Care Surveys; Health Services Accessibility; Healthcare Disparities; Humans; Hyperlipoproteinemia Type II; Phenotype; Predictive Value of Tests; Prevalence; Risk Factors; Treatment Outcome; Blood Component Removal; Global Health; International CooperationEAS Familial Hypercholesterolaemia Studies Collaboration3. Good healthPREVALENCECholesterolPhenotypeTreatment OutcomeBlood Component RemovalCORONARY-ARTERY-DISEASENATIONWIDE SURVEYCardiology and Cardiovascular MedicineFamilial hypercholesterolaemiamedicine.medical_specialtyCardiovascular risk factorsPopulationLDL-RECEPTOR1102 Cardiovascular Medicine And HaematologyLDLHyperlipoproteinemia Type II03 medical and health sciencesPredictive Value of TestsmedicineHumans:Medicine [Science]Genetic Predisposition to DiseasePrimary dyslipidaemiaHealthcare Disparitiesfhsc; familial hypercholesterolaemia; primary dyslipidaemiaeducationGenetic testingGovernmentPublic healthEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) InvestigatorsSAFEHEART REGISTRY1103 Clinical SciencesFHSCCholesterol LDLCardiovascular System & HematologyFamily medicineHealth Care Surveys3121 General medicine internal medicine and other clinical medicineCardiovascular System & CardiologyBusinessFOLLOW-UPBiomarkers
researchProduct

New physics in the kinematic distributions of $\bar B\to D^{(*)}\tau^-(\to\ell^-\bar\nu_\ell\nu_\tau)\bar\nu_\tau$

2016

We investigate the experimentally-accessible kinematic distributions of the $\bar B\to D^{(*)}\tau^-(\to\ell^-\bar\nu_\ell\nu_\tau)\bar\nu_\tau$ decays. Specifically, we study the decay rates as functions of the $B\to D^{(*)}$ transferred squared momentum, the energy of the final charged lepton and the angle of its 3-momentum relative to the 3-momentum of the recoiling $D^{(*)}$. The angular distribution allows to introduce new observables, like a forward-backward asymmetry, which are complementary to the total rates. We present analytic formulas for the observable 3-fold 5-body differential decay rates, study the predictions in the Standard Model and investigate the effects in different ne…

High Energy Physics - PhenomenologyHigh Energy Physics::PhenomenologyHigh Energy Physics::ExperimentHigh Energy Physics - Experiment
researchProduct

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

2021

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Dat…

MaleSettore MED/09 - Medicina InternaArterial diseaseCross-sectional studyAdult populationCoronary DiseaseDiseaseGlobal HealthMedical and Health SciencesDoenças Cardio e Cérebro-vascularesAnticholesteremic AgentMonoclonalPrevalenceRegistriesFamilial HypercholesterolemiaHumanizedStroke11 Medical and Health SciencesLS2_9Studies CollaborationAnticholesteremic AgentsGeneral MedicineHeart Disease Risk FactorMiddle AgedFHSC global registry dataEuropeTreatment OutcomeLower prevalenceGuidancelipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Familial hypercholesterolaemiaLife Sciences & BiomedicineHumanAdultmedicine.medical_specialtyCombination therapyFHSC global registry heterozygous familial hypercholesterolaemiaCardiovascular risk factorsAntibodies Monoclonal HumanizedInsightsAntibodiesNOHyperlipoproteinemia Type IIClinicianMedicine General & InternalInternal medicineGeneral & Internal MedicineHealth SciencesmedicineHumansEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)Cross-Sectional StudieScience & TechnologyGlobal Perspectivebusiness.industryCholesterol LDLmedicine.diseaseCross-Sectional StudiesHeart Disease Risk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

Familial hypercholesterolaemia: A global call to arms

2015

Familial Hypercholesterolaemia (FH) is the commonest autosomal co-dominantly inherited condition affecting man. It is caused by mutation in one of three genes, encoding the low-density lipoprotein (LDL) receptor, or the gene for apolipoprotein B (which is the major protein component of the LDL particle), or in the gene coding for PCSK9 (which is involved in the degradation of the LDL-receptor during its cellular recycling). These mutations result in impaired LDL metabolism, leading to life-long elevations in LDL-cholesterol (LDL-C) and development of premature atherosclerotic cardiovascular disease (ASCVD) [1], [2] and [3]. If left untreated, the relative risk of premature coronary artery d…

PathologyApolipoprotein BDisease030204 cardiovascular system & hematologymedicine.disease_causeGlobal HealthDISEASEDoenças Cardio e Cérebro-vasculares0302 clinical medicineHyperlipoproteinemia Type IISocieties MedicalRISK0303 health sciencesMutationbiology3. Good healthPREVALENCEEuropelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineFamilial hypercholesterolaemiaLife Sciences & Biomedicinemedicine.medical_specialtyHeterozygote1102 Cardiovascular Medicine And HaematologyHyperlipoproteinemia Type II03 medical and health sciencesInternal medicinemedicineHumans030304 developmental biologyScience & Technologybusiness.industryGUIDANCEPCSK9Heterozygote advantage1103 Clinical SciencesEndocrinologyPeripheral Vascular DiseaseCardiovascular System & HematologyReceptors LDLRECEPTORES DE LIPOPROTEÍNASRelative riskMutationbiology.proteinCardiovascular System & CardiologyFamilial HypercholesterolaemiabusinessCLINICIANLipoprotein
researchProduct

Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide

2015

Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised by markedly elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C). Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor approved as an adjunct to other lipid-lowering therapies (LLTs), with or without lipoprotein apheresis (LA), for the treatment of adult HoFH. Diet with <20% calories from fat is required. Due to a varying genetic and phenotypic profile of patients with HoFH, individual patients may respond to therapy differently; therefore examining individual cases in a 'real-world' setting provides valuable information on the effective day-to-day manag…

AdultMalemedicine.medical_specialtyCalorieSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismCase studyFamilial hypercholesterolemiaHomozygous familial hypercholesterolemiaFamilial hypercholesterolemiaDiseaseCompound heterozygosityHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicineCase study; Familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Lomitapide; Treatment; Cardiology and Cardiovascular Medicine; Endocrinology Diabetes and Metabolism; Internal Medicine; Nutrition and DieteticsInternal MedicinemedicineHumansAdverse effectNutrition and Dieteticsbusiness.industryAnticholesteremic AgentsHomozygoteCholesterol LDLMiddle Agedmedicine.diseaseLomitapideLomitapideTreatmentClinical trialEndocrinologychemistryBenzimidazolesFemaleSteatosisCardiology and Cardiovascular Medicinebusiness
researchProduct

Lepton universality violation with lepton flavor conservation in B-meson decays

2015

Anomalies in semileptonic B-meson decays present interesting patterns that might be revealing the shape of the new physics to come. Under the assumption that neutrino and charged lepton mass terms are the only sources of flavor violation and given the hierarchy between the two, we find that charged lepton universality violation without charged lepton flavor violation naturally arises. This can account for a deficit of B + → K + μμ over B + → K + ee decays with new physics coupled predominantly to muons and a new physics scale of a few TeV. A generic prediction of this scenario is a large enhacement of tauonic B decay rates that, in particular, could accommodate an excess in B → D (∗) τ ν. F…

Particle physicsNuclear and High Energy PhysicsPhysics beyond the Standard ModelB-PhysicsAtomicMathematical SciencesParticle and Plasma PhysicsEffective field theoryLeptoquarkB mesonNuclearMathematical PhysicsPhysicsQuantum PhysicsMuonRare DecaysHigh Energy Physics::PhenomenologyMolecularObservablehep-phNuclear & Particles PhysicsPhysical SciencesBeyond Standard ModelHigh Energy Physics::ExperimentNeutrinoLeptonJournal of High Energy Physics
researchProduct

New physics in the kinematic distributions of B¯→D(*)τ−(→ℓ−ν¯ℓντ)ν¯τ

2016

We investigate the experimentally accessible kinematic distributions of the $\overline{B}\ensuremath{\rightarrow}{D}^{(*)}{\ensuremath{\tau}}^{\ensuremath{-}}(\ensuremath{\rightarrow}{\ensuremath{\ell}}^{\ensuremath{-}}{\overline{\ensuremath{\nu}}}_{\ensuremath{\ell}}{\ensuremath{\nu}}_{\ensuremath{\tau}}){\overline{\ensuremath{\nu}}}_{\ensuremath{\tau}}$ decays. Specifically, we study the decay rates as functions of the $B\ensuremath{\rightarrow}{D}^{(*)}$ transferred squared momentum, the energy of the final charged lepton and the angle of its 3-momentum with respect to the 3-momentum of the recoiling ${D}^{(*)}$. The angular distribution allows to introduce new observables, like a forwar…

PhysicsParticle physics010308 nuclear & particles physicsPhysics beyond the Standard ModelHigh Energy Physics::PhenomenologyForm factor (quantum field theory)Observable01 natural sciencesStandard ModelMomentum0103 physical sciencesEffective field theory010306 general physicsEnergy (signal processing)LeptonPhysical Review D
researchProduct

SU(2)×U(1)Gauge Invariance and the Shape of New Physics in RareBDecays

2014

New physics effects in B decays are routinely modeled through operators invariant under the strong and electromagnetic gauge symmetries. Assuming the scale for new physics is well above the electroweak scale, we further require invariance under the full standard model gauge symmetry group. Retaining up to dimension-six operators, we unveil new constraints between different new physics operators that are assumed to be independent in the standard phenomenological analyses. We illustrate this approach by analyzing the constraints on new physics from rare B(q) (semi-)leptonic decays.

PhysicsParticle physicsGauge bosonPhysics beyond the Standard ModelGeneral Physics and AstronomyGauge theoryElectroweak scaleInvariant (physics)U-1Special unitary groupGauge symmetryPhysical Review Letters
researchProduct

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and …

2016

WOS: 000393031600001

PREDICTIONInternational CooperationPoolingInformation Storage and RetrievalDisease030204 cardiovascular system & hematologyGUIDELINESDoenças Cardio e Cérebro-vascularesLDL-Cholesterol0302 clinical medicineCardiovascular DiseaseMedicineData MiningCardiac and Cardiovascular Systems030212 general & internal medicineRegistriesDisease management (health)Cooperative BehaviorGENERAL-POPULATIONRISKFamilial hypercholesterolaemia ; LDL-Cholesterol ; Cardiovascular disease ; RegistryKardiologiCONSENSUS PANELDelivery of Health Care IntegratedGeneral MedicineOrvostudományokCardiovascular diseasePREVALENCE3. Good healthTreatment OutcomeCARDIOVASCULAR-DISEASEResearch DesignFamilial hypercholesterolaemiaCardiology and Cardiovascular MedicineRegistrymedicine.medical_specialtyBest practiceKlinikai orvostudományokAccess to InformationHyperlipoproteinemia Type II03 medical and health sciencesEUROPEAN ATHEROSCLEROSIS SOCIETYInternal MedicineHumansOrganizational ObjectivesBespokeStudy DesignGUIDANCEbusiness.industryPublic healthStudy designProfessional Practice GapsData sharingClinical trialCardiovascular System & Hematology3121 General medicine internal medicine and other clinical medicineFamily medicineFamilial hypercholesterolaemia; LDL-Cholesterol; Cardiovascular disease; Registry; Study design; Familial Hypercholesterolaemia Studies CollaborationFamilial Hypercholesterolaemia Studies CollaborationFamilial HypercholesterolaemiaINDIVIDUAL PARTICIPANT DATAbusiness
researchProduct

Lepton universality violation and lepton flavor conservation in $B$-meson decays

2015

Anomalies in (semi)leptonic $B$-meson decays present interesting patterns that might be revealing the shape of the new physics to come. In order to understand the experimental data, we explore symmetry arguments that lead to the hypothesis of minimal flavor violation. In particular, under the assumption of negligible neutrino mass effects in charged lepton processes, the presence of lepton universality violation without lepton flavor violation naturally arises. This can account for a deficit of $B^+\to K^+\mu\mu$ over $B^+\to K^+ee$ decays with new physics coupled predominantly to muons and a new physics scale of a few TeV. A prediction of this scenario is the modification of processes invo…

High Energy Physics - PhenomenologyHigh Energy Physics - Phenomenology (hep-ph)High Energy Physics::PhenomenologyFOS: Physical sciencesHigh Energy Physics::Experiment
researchProduct